340 related articles for article (PubMed ID: 32675593)
21. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
22. AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging.
Salminen A; Kauppinen A; Kaarniranta K
J Mol Med (Berl); 2019 Aug; 97(8):1049-1064. PubMed ID: 31129755
[TBL] [Abstract][Full Text] [Related]
23. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
24. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
25. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K
Front Immunol; 2022; 13():1016059. PubMed ID: 36304465
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
Koinis F; Xagara A; Chantzara E; Leontopoulou V; Aidarinis C; Kotsakis A
Cells; 2021 Dec; 11(1):. PubMed ID: 35011582
[TBL] [Abstract][Full Text] [Related]
29. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
31. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.
Li L; Li M; Jia Q
Pathol Res Pract; 2023 Aug; 248():154711. PubMed ID: 37494802
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.
Baniyash M
Cancer Immunol Immunother; 2016 Jul; 65(7):857-67. PubMed ID: 27225641
[TBL] [Abstract][Full Text] [Related]
33. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
34. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
Toor SM; Elkord E
Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
[TBL] [Abstract][Full Text] [Related]
36. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
[TBL] [Abstract][Full Text] [Related]
37. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
Front Immunol; 2020; 11():737. PubMed ID: 32391020
[TBL] [Abstract][Full Text] [Related]
38. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
[TBL] [Abstract][Full Text] [Related]
40. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.
Ma C; Zhang Q; Greten TF
Cell Immunol; 2021 Mar; 361():104295. PubMed ID: 33508529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]